Healthcare Industry News: S.A.
News Release - June 18, 2014
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
SARASOTA, Fla., June 18, 2014 -- (Healthcare Sales & Marketing Network) -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has raised a total of $5.5 million, before feeS.A.d expenses, through a Series C Preferred stock offering from a group of accredited investors. S.A.S.A.e Equities LLC of New York and San Francisco acted as the principal placement agent. The Company will use the proceeds to advance is novel broad-spectrum Bisphosphocin™ class of antimicrobials into human clinical trials.Lakewood-Amedex CFO, E. Russell McAllister, who joined the Company in January and managed the relationships with S.A.S.A.e EquitieS.A.d Capital Guardian LLC, also a placement agent in the financing, remarked, "The Series C funding markS.A.major milestone for Lakewood-Amedex, providing the Company with sufficient capital to complete its first two human clinical trials for its lead Bisphosphocin™ product, Nu-3: a Phase I/IIa trial for infected complicated diabetic foot ulcers (cDFU), a topical indication, followed by a Phase I trial for several systemic infections such as complicated urinary tract infections (cUTI) by intravenouS.A.ministration. These indications were specifically selected to rapidly demonstrate the broad-spectrum activity of the Bisphosphocin™ clasS.A.ainst problematic chronic and acute infections due to their rapid bactericidal effect. Bisphosphocins™ represent a new paradigm in antimicrobial development because they are effective against both, gram-positive and gram-negative bacteria, including those caused by antibiotic-resiS.A.t strains such as MRSA, ES.A.E, and NDM-1 strainS.A. well as biofilm encased bacteria."
Lakewood-Amedex intends to significantly increase its business development activitieS.A. a result of this funding, including seeking collaborationS.A.d partnerships to help develop its extensive portfolio of products. In particular, the Company will be seeking partners to continue development of its orally available 'gene silencing' nRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditionS.A.d other chronic human diS.A.es.
Mr. McAllister continued, "It has been a pleasure to work with my former colleagueS.A. both S.A.S.A.e EquitieS.A.d Capital Guardian in bringing about this financing through our relationships with knowledgeable and sophisticated investors that were able to appreciate the commercial and medical potential of our novel product portfolio."
About Lakewood-Amedex, Inc.
Lakewood-Amedex iS.A.privately held biopharmaceutical company developing a broad portfolio of innovative novel-approach anti-infective products in the treatment of serious infectious diS.A.es, improving patient outcomeS.A.d significantly reducing the threat posed by antibiotic-resiS.A.t bacterial strains like MRSA, VRE, NDM-1 and biofilm strains. The Company's productS.A.d technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents. The Company's lead product, Nu-3, a first-in-clasS.A.timicrobial, is expected to enter the clinic in the second half of 2014. Lakewood-Amedex iS.A.so developing orally available 'gene silencing' nRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditionS.A.d other chronic human diS.A.es.
About S.A.S.A.e Equities LLC
S.A.S.A.e Equities LLC iS.A. institutional FINRA member broker/dealer and SIPC member located in New York City, U.S.A., with officeS.A. 10 Rockefeller Plaza in midtown Manhattan. The founding partners of S.A.S.A.e Equities LLC are respected veterans of the U.S. financial services industry with solid track recordS.A. investors, analysts, and investment bankers.
About Capital Guardian LLC
Capital Guardian iS.A.boutique wealth management firm with offices strategically located throughout the United S.A.es. Capital Guardian offerS.A.visorS.A.cess to a true open platform, personalized support, global resourceS.A.d an innovative management team. The firm's mission is to liberate and empower investorS.A.d advisors.
This press release contains forward-looking S.A.ements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking S.A.ements regarding our business, which are not historical facts, are "forward-looking S.A.ements" that involve risk and uncertainties, which could cause the Company'S.A.tual resultS.A.d financial condition to differ materially from those anticipated by the forward-looking S.A.ements. Actual results may differ materially from S.A.ements made aS.A.result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product reS.A.ch and development, risk of protecting proprietary rightS.A.d competition. Forward-looking S.A.ements speak only as to the date they are made. The Company does not undertake to update forward-looking S.A.ements to reflect the circumS.A.ces or events that occur after the date the forward-looking S.A.ementS.A.e made.
Source: Lakewood-Amedex
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!